Cannabinoid treatment for the symptoms of autism spectrum disorder

References

• Lord C, Elsabbagh M, Baird G, et al. Autism spectrum disorder. Lancet (London, England). 2018 Aug 11;392(10146):508–520. doi: 10.1016/S0140-6736(18)31129-2
   PubMed Web of Science ®Google Scholar
• Hirota T, King BH. Autism Spectrum Disorder: A Review. JAMA. 2023 Jan 10;329(2):157–168. doi: 10.1001/jama.2022.23661
   PubMed Web of Science ®Google Scholar
• Maenner M, Warren Z, Robinson-Williams A, et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years — autism and developmental disabilities monitoring network, 11 Sites, United States, 2020. Cdc, editor. CDC: CDC; 2023.
   Google Scholar
• Szkudlarek HJ, Desai SJ, Renard J, et al. Delta-9-tetrahydrocannabinol and cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors. Neuropsychopharmacology. 2019 Mar;44(4):817–825.
   PubMed Web of Science ®Google Scholar
• Castillo-Arellano J, Canseco-Alba A, Cutler SJ, et al. The polypharmacological effects of cannabidiol. Molecules. 2023 Apr 6;28(7):3271. doi: 10.3390/molecules28073271
   PubMed Web of Science ®Google Scholar
• Felberbaum M. 2018. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611046.htm
   Google Scholar
• Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017 May 25;376(21):2011–2020. doi: 10.1056/NEJMoa1611618
   PubMed Web of Science ®Google Scholar
• Devinsky O, Patel AD, Cross JH, et al. Effect Of cannabidiol on drop seizures in the lennox-gastaut syndrome. N Engl J Med. 2018 May 17;378(20):1888–1897. doi: 10.1056/NEJMoa1714631
   PubMed Web of Science ®Google Scholar
• Thiele EA, Bebin EM, Bhathal H, et al. Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial. JAMA Neurol. 2021 Mar 1;78(3):285–292. doi: 10.1001/jamaneurol.2020.4607
   PubMed Web of Science ®Google Scholar
• Aran A, Cassuto H, Lubotzky A, et al. Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems-a retrospective feasibility study. J Autism Dev Disord. 2019 Mar;49(3):1284–1288.
   PubMed Web of Science ®Google Scholar
• Barchel D, Stolar O, De-Haan T, et al. Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and Co-morbidities. Front Pharmacol. 2018;9:1521. doi: 10.3389/fphar.2018.01521
   PubMed Web of Science ®Google Scholar
• Fleury-Teixeira P, Caixeta FV, Ramires da Silva LC, et al. Effects of CBD-Enriched cannabis sativa extract on autism spectrum disorder symptoms: an observational study of 18 participants undergoing compassionate use. Front Neurol. 2019;10:1145. doi: 10.3389/fneur.2019.01145
   PubMed Web of Science ®Google Scholar
• Bar-Lev Schleider L, Mechoulam R, Saban N, et al. Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep. 2019 Jan 17;9(1):200.
   PubMedGoogle Scholar
• Montagner PSS, Medeiros W, da Silva LCR, et al. Individually tailored dosage regimen of full-spectrum cannabis extracts for autistic core and comorbid symptoms: a real-life report of multi-symptomatic benefits. Front Psychiatry. 2023;14:1210155. doi: 10.3389/fpsyt.2023.1210155
   PubMed Web of Science ®Google Scholar
• Hacohen M, Stolar OE, Berkovitch M, et al. Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study. Transl Psychiatry. 2022 Sep 9;12(1):375. doi: 10.1038/s41398-022-02104-8
   PubMed Web of Science ®Google Scholar
• Stolar O, Hazan A, Vissoker RE, et al. Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: an interim analysis of biochemical safety. Front Pharmacol. 2022;13:977484. doi: 10.3389/fphar.2022.977484
   PubMed Web of Science ®Google Scholar
• Bilge S, Ekici B. CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature. J Cannabis Res. 2021 Dec 16;3(1):53. doi: 10.1186/s42238-021-00108-7
   PubMedGoogle Scholar
• Buescher AV, Cidav Z, Knapp M, et al. Costs of autism spectrum disorders in the United Kingdom and the United States. JAMA Pediatr. 2014 Aug;168(8):721–728. doi: 10.1001/jamapediatrics.2014.210
   PubMed Web of Science ®Google Scholar
• Goel R, Hong JS, Findling RL, et al. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Inter Rev Psychiatry (Abingdon England). 2018 Feb;30(1):78–95. doi: 10.1080/09540261.2018.1458706
   PubMed Web of Science ®Google Scholar
• Iffland M, Livingstone N, Jorgensen M, et al. Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD). Cochrane Database Syst Rev. 2023 Oct 9;10(10):Cd011769. doi: 10.1002/14651858.CD011769.pub2
   PubMedGoogle Scholar
• Fieiras C, Chen MH, Escobar Liquitay CM, et al. Risperidone and aripiprazole for autism spectrum disorder in children: an overview of systematic reviews. BMJ Evid Based Med. 2023 Feb;28(1):7–14.
   PubMedGoogle Scholar
• Salazar de Pablo G, Pastor Jordá C, Vaquerizo-Serrano J, et al. Systematic review and meta-analysis: efficacy of pharmacological interventions for irritability and emotional dysregulation in autism spectrum disorder and predictors of response. Journal Of The American Academy Of Child & Adolescent Psychiatry. 2023 Feb;62(2):151–168.
   PubMed Web of Science ®Google Scholar
• Pruneti C, Coscioni G, Guidotti S. Evaluation of the effectiveness of behavioral interventions for autism spectrum disorders: a systematic review of randomized controlled trials and quasi-experimental studies. Clin Child Psychol Psychiatry. 2023 Oct 6;29(1):213–231. doi: 10.1177/13591045231205614
   PubMed Web of Science ®Google Scholar
• Sikich L, Kolevzon A, King BH, et al. Intranasal oxytocin in children and adolescents with autism spectrum disorder. N Engl J Med. 2021 Oct 14;385(16):1462–1473. doi: 10.1056/NEJMoa2103583
   PubMed Web of Science ®Google Scholar
• Guastella AJ, Boulton KA, Whitehouse AJO, et al. The effect of oxytocin nasal spray on social interaction in young children with autism: a randomized clinical trial. Mol Psychiatry. 2023 Feb;28(2):834–842.
   PubMed Web of Science ®Google Scholar
• Daniels N, Moerkerke M, Steyaert J, et al. Effects of multiple-dose intranasal oxytocin administration on social responsiveness in children with autism: a randomized, placebo-controlled trial. Mol Autism. 2023 Apr 20;14(1):16. doi: 10.1186/s13229-023-00546-5
   PubMed Web of Science ®Google Scholar
• Hollander E, Jacob S, Jou R, et al. Balovaptan vs placebo for social communication in childhood autism spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2022 Aug 1;79(8):760–769. doi: 10.1001/jamapsychiatry.2022.1717
   PubMed Web of Science ®Google Scholar
• Jacob S, Veenstra-VanderWeele J, Murphy D, et al. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. Lancet Psychiatry. 2022 Mar;9(3):199–210.
   PubMed Web of Science ®Google Scholar
• Fuentes J, Parellada M, Georgoula C, et al. Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: results from two randomized phase III studies. Autism Res. 2023 Oct 4;16(10):2021–2034. doi: 10.1002/aur.3005
   PubMed Web of Science ®Google Scholar
• Ou J, Smith RC, Tobe RH, et al. Efficacy of sulforaphane in treatment of children with autism spectrum disorder: a randomized double-blind placebo-controlled multi-center trial. J Autism Dev Disord. 2022 Nov 24. doi: 10.1007/s10803-022-05784-9
   Web of Science ®Google Scholar
• Dai Y, Zhang L, Yu J, et al. Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial. Sci Bull (Beijing). 2021 Aug 15;66(15):1591–1598. doi: 10.1016/j.scib.2021.01.008
   PubMed Web of Science ®Google Scholar
• Yamasue H, Kojima M, Kuwabara H, et al. Effect of a novel nasal oxytocin spray with enhanced bioavailability on autism: a randomized trial. Brain. 2022 Apr 18;145(2):490–499. doi: 10.1093/brain/awab291
   PubMed Web of Science ®Google Scholar
• Bolognani F, Del Valle Rubido M, Squassante L, et al. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Sci Transl Med. 2019 May 8;11(491). doi: 10.1126/scitranslmed.aat7838
   Web of Science ®Google Scholar
• Kimi S, Maiti R, Srinivasan A, et al. Efficacy and safety of V(1a) receptor antagonists in autism spectrum disorder: a meta-analysis. Int J Dev Neurosci. 2023 Aug 28. doi: 10.1002/jdn.10297
   Web of Science ®Google Scholar
• Hu L, Du X, Jiang Z, et al. Oxytocin treatment for core symptoms in children with autism spectrum disorder: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2023 Oct;79(10):1357–1363.
   PubMed Web of Science ®Google Scholar
• Lee TM, Lee KM, Lee CY, et al. Effectiveness of N-acetylcysteine in autism spectrum disorders: a meta-analysis of randomized controlled trials. Aust N Z J Psychiatry. 2021 Feb;55(2):196–206.
   PubMed Web of Science ®Google Scholar
• Rodrigues R, Lai MC, Beswick A, et al. Practitioner review: pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis. J Child Psychol Psychiatr. 2021 Jun;62(6):680–700.
   PubMed Web of Science ®Google Scholar
• Scahill L, McCracken JT, King BH, et al. Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. Am J Psychiatry. 2015 Dec;172(12):1197–206.
   PubMed Web of Science ®Google Scholar
• Gringras P, Nir T, Breddy J, et al. Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2017 Nov;56(11):948–957.e4.
   PubMed Web of Science ®Google Scholar
• Siafis S, Çıray O, Wu H, et al. Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Mol Autism. 2022 Mar 4;13(1):10. doi: 10.1186/s13229-022-00488-4
   PubMed Web of Science ®Google Scholar
• Liang SC, Sun CK, Fan HY, et al. Therapeutic effects of antidepressants for global improvement and subdomain symptoms of autism spectrum disorder: a systematic review and meta-analysis. J Psychiatry Neurosci. 2022 Jul;47(4):E299–e310.
   PubMed Web of Science ®Google Scholar
• Limbu B, Deb S, Roy M, et al. Randomised controlled trials of mood stabilisers for people with autism spectrum disorder: systematic review and meta-analysis. BJPsych Open. 2022 Feb 24;8(2):e52. doi: 10.1192/bjo.2022.18
   PubMed Web of Science ®Google Scholar
• Ure A, Cox GR, Haslam R, et al. Acetylcholinesterase inhibitors for autistic spectrum disorders. Cochrane Database Syst Rev. 2023 Jun 1;6(6):Cd013851. doi: 10.1002/14651858.CD013851.pub2
   PubMedGoogle Scholar
• Brignell A, Marraffa C, Williams K, et al. Memantine for autism spectrum disorder. Cochrane Database Syst Rev. 2022 Aug 25;8(8):Cd013845. doi: 10.1002/14651858.CD013845.pub2
   PubMedGoogle Scholar
• de la Torre-Aguilar MJ, Gomez-Fernandez A, Flores-Rojas K, et al. Docosahexaenoic and eicosapentaenoic intervention modifies plasma and erythrocyte omega-3 fatty acid profiles but not the clinical course of children with autism spectrum disorder: a randomized control trial. Front Nutr. 2022;9:790250.
   PubMed Web of Science ®Google Scholar
• Jacob S, Anagnostou E, Hollander E, et al. Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program. Mol Autism. 2022 Jun 11;13(1):25. doi: 10.1186/s13229-022-00505-6
   PubMed Web of Science ®Google Scholar
• McPartland JC, Bernier RA, Jeste SS, et al. ThE autism biomarkers consortium for clinical trials (abc-ct): scientific context, study design, and progress toward biomarker qualification. Front Integr Neurosci. 2020;14:16. doi: 10.3389/fnint.2020.00016
   PubMed Web of Science ®Google Scholar
• Siafis S, Çıray O, Schneider-Thoma J, et al. Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis. Mol Autism. 2020 Aug 26;11(1):66. doi: 10.1186/s13229-020-00372-z
   PubMed Web of Science ®Google Scholar
• Faja S, Sabatos-DeVito M, Sridhar A, et al. Evaluation of clinical assessments of social abilities for use in autism clinical trials by the autism biomarkers consortium for clinical trials. Autism Res. 2023 May;16(5):981–996.
   PubMed Web of Science ®Google Scholar
• Satterstrom FK, Kosmicki JA, Wang J, et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell. 2020 Feb 6;180(3):568–584.e23. doi: 10.1016/j.cell.2019.12.036
   PubMed Web of Science ®Google Scholar
• Fadila S, Beucher B, Dopeso-Reyes IG, et al. Viral vector-mediated expression of NaV1.1, after seizure onset, reduces epilepsy in mice with Dravet syndrome. J Clin Invest. 2023 Jun 15;133(12). doi: 10.1172/JCI159316
   PubMed Web of Science ®Google Scholar
• Tamura S, Nelson A, Spratt P, et al. CRISPR activation rescues abnormalities in SCN2A haploinsufficiency-associated autism spectrum disorder. bioRxiv. 2022. https://www.biorxiv.org/content/10.1101/2022.03.30.486483v1
   Google Scholar
• Jourdon A, Wu F, Mariani J, et al. Modeling idiopathic autism in forebrain organoids reveals an imbalance of excitatory cortical neuron subtypes during early neurogenesis. Nat Neurosci. 2023 Sep;26(9):1505–1515.
   PubMed Web of Science ®Google Scholar
• Modabbernia A, Velthorst E, Reichenberg A. Environmental risk factors for autism: an evidence-based review of systematic reviews and meta-analyses. Mol Autism. 2017;8(1):13. doi: 10.1186/s13229-017-0121-4
   PubMed Web of Science ®Google Scholar
• Guerrero-Alba R, Barragan-Iglesias P, Gonzalez-Hernandez A, et al. Some prospective alternatives for treating pain: the endocannabinoid system and its putative receptors GPR18 and GPR55. Front Pharmacol. 2018;9:1496. doi: 10.3389/fphar.2018.01496
   PubMed Web of Science ®Google Scholar
• Melancia F, Schiavi S, Servadio M, et al. Sex-specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signalling. Br J Pharmacol. 2018 Sep;175(18):3699–3712.
   PubMed Web of Science ®Google Scholar
• Zamberletti E, Gabaglio M, Parolaro D. The endocannabinoid system and autism spectrum disorders: insights from animal models. Int J Mol Sci. 2017 Sep 7;18(9):1916. doi: 10.3390/ijms18091916
   PubMed Web of Science ®Google Scholar
• Wang W, Cox BM, Jia Y, et al. Treating a novel plasticity defect rescues episodic memory in Fragile X model mice. Mol Psychiatry. 2018 Aug;23(8):1798–1806.
   PubMed Web of Science ®Google Scholar
• Hosie S, Malone DT, Liu S, et al. Altered amygdala excitation and CB1 receptor modulation of aggressive behavior in the neuroligin-3(R451C) mouse model of autism. Front Cell Neurosci. 2018;12:234.
   PubMed Web of Science ®Google Scholar
• Poleg S, Kourieh E, Ruban A, et al. Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder. Transl Psychiatry. 2021 Oct 13;11(1):524. doi: 10.1038/s41398-021-01612-3
   PubMed Web of Science ®Google Scholar
• Zou M, Liu Y, Xie S, et al. Alterations of the endocannabinoid system and its therapeutic potential in autism spectrum disorder. Open Biol. 2021 Feb;11(2):200306. doi: 10.1098/rsob.200306
   PubMed Web of Science ®Google Scholar
• Schiavi S, Manduca A, Carbone E, et al. Anandamide and 2-arachidonoylglycerol differentially modulate autistic-like traits in a genetic model of autism based on FMR1 deletion in rats. Neuropsychopharmacology. 2023 May;48(6):897–907.
   PubMed Web of Science ®Google Scholar
• Hurley MJ, Deacon RMJ, Chan AWE, et al. Reversal of behavioural phenotype by the cannabinoid-like compound VSN16R in fragile X syndrome mice. Brain. 2022 Mar 29;145(1):76–82. doi: 10.1093/brain/awab246
   PubMed Web of Science ®Google Scholar
• Karhson DS, Krasinska KM, Dallaire JA, et al. Plasma anandamide concentrations are lower in children with autism spectrum disorder. Mol Autism. 2018;9(1):18. doi: 10.1186/s13229-018-0203-y
   PubMedGoogle Scholar
• Aran A, Eylon M, Harel M, et al. Lower circulating endocannabinoid levels in children with autism spectrum disorder. Mol Autism. 2019;10(1):2. doi: 10.1186/s13229-019-0256-6
   PubMedGoogle Scholar
• Boggs DL, Nguyen JD, Morgenson D, et al. Clinical and preclinical evidence for functional interactions of cannabidiol and Δ(9)-Tetrahydrocannabinol. Neuropsychopharmacology. 2018 Jan;43(1):142–154.
   PubMed Web of Science ®Google Scholar
• Kozela E, Pietr M, Juknat A, et al. Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem. 2010 Jan 15;285(3):1616–1626. doi: 10.1074/jbc.M109.069294
   PubMed Web of Science ®Google Scholar
• Juknat A, Pietr M, Kozela E, et al. Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells. Br J Pharmacol. 2012 Apr;165(8):2512–28.
   PubMed Web of Science ®Google Scholar
• Juknat A, Pietr M, Kozela E, et al. Microarray and pathway analysis reveal distinct mechanisms underlying cannabinoid-mediated modulation of LPS-induced activation of BV-2 microglial cells. PloS One. 2013;8(4):e61462. doi: 10.1371/journal.pone.0061462
   PubMed Web of Science ®Google Scholar
• Juknat A, Gao F, Coppola G, et al. miRNA expression profiles and molecular networks in resting and LPS-activated BV-2 microglia-Effect of cannabinoids. PloS One. 2019;14(2):e0212039. doi: 10.1371/journal.pone.0212039
   PubMed Web of Science ®Google Scholar
• Silva-Cardoso GK, Lazarini-Lopes W, Primini EO, et al. Cannabidiol modulates chronic neuropathic pain aversion behavior by attenuation of neuroinflammation markers and neuronal activity in the corticolimbic circuit in male Wistar rats. Behav Brain Res. 2023 Aug 24;452:114588. doi: 10.1016/j.bbr.2023.114588
   PubMed Web of Science ®Google Scholar
• Cifelli P, Ruffolo G, De Felice E, et al. Phytocannabinoids in neurological diseases: could they restore a physiological GABAergic Transmission? Int J Mol Sci. 2020 Jan 22;21(3):723. doi: 10.3390/ijms21030723
   PubMed Web of Science ®Google Scholar
• Gonca E, Darıcı F. The effect of cannabidiol on ischemia/reperfusion-induced ventricular arrhythmias: the role of adenosine A1 receptors. J Cardiovasc Pharmacol Ther. 2015 Jan;20(1):76–83. doi: 10.1177/1074248414532013
   PubMed Web of Science ®Google Scholar
• Ribeiro A, Ferraz-de-Paula V, Pinheiro ML, et al. Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor. Eur J Pharmacol. 2012 Mar 5;678(1–3):78–85. doi: 10.1016/j.ejphar.2011.12.043
   PubMed Web of Science ®Google Scholar
• Campos AC, Guimarães FS. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacol (Berl). 2008 Aug;199(2):223–30. doi: 10.1007/s00213-008-1168-x
   PubMed Web of Science ®Google Scholar
• Hind WH, England TJ, O’Sullivan SE. Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors. Br J Pharmacol. 2016 Mar;173(5):815–825. doi: 10.1111/bph.13368
   PubMed Web of Science ®Google Scholar
• Iannotti FA, Hill CL, Leo A, et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci. 2014 Nov 19;5(11):1131–41. doi: 10.1021/cn5000524
   PubMed Web of Science ®Google Scholar
• Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092–101.
   PubMed Web of Science ®Google Scholar
• Huang J, Fan X, Jin X, et al. Cannabidiol inhibits Na(v) channels through two distinct binding sites. Nat Commun. 2023 Jun 17;14(1):3613. doi: 10.1038/s41467-023-39307-6
   PubMed Web of Science ®Google Scholar
• Keller R, Basta R, Salerno L, et al. Autism, epilepsy, and synaptopathies: a not rare association. Neurol Sci. 2017 Aug;38(8):1353–1361. doi: 10.1007/s10072-017-2974-x
   PubMed Web of Science ®Google Scholar
• Vargas DL, Nascimbene C, Krishnan C, et al. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005 Jan;57(1):67–81.
   PubMed Web of Science ®Google Scholar
• Morgan JT, Chana G, Pardo CA, et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry. 2010 Aug 15;68(4):368–76. doi: 10.1016/j.biopsych.2010.05.024
   PubMed Web of Science ®Google Scholar
• Suzuki K, Sugihara G, Ouchi Y, et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry. 2013 Jan;70(1):49–58.
   PubMed Web of Science ®Google Scholar
• Salter MW, Beggs S. Sublime microglia: expanding roles for the guardians of the CNS. Cell. 2014 Jul 3;158(1):15–24. doi: 10.1016/j.cell.2014.06.008
   PubMed Web of Science ®Google Scholar
• Schafer DP, Heller CT, Gunner G, et al. Microglia contribute to circuit defects in Mecp2 null mice independent of microglia-specific loss of Mecp2 expression. Elife. 2016 Jul 26;5. doi: 10.7554/eLife.15224
   Web of Science ®Google Scholar
• Matcovitch-Natan O, Winter DR, Giladi A, et al. Microglia development follows a stepwise program to regulate brain homeostasis. Science. 2016 Aug 19;353(6301):aad8670. doi: 10.1126/science.aad8670
   PubMed Web of Science ®Google Scholar
• Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med. 2017 Sep 8;23(9):1018–1027. doi: 10.1038/nm.4397
   PubMed Web of Science ®Google Scholar
• Zhang L, Lin C, Zhu J, et al. Restoring prefrontal cortical excitation-inhibition balance with cannabidiol ameliorates neurobehavioral abnormalities in a mouse model of neurodevelopmental disorders. Neuropharmacology. 2023 Dec 1;240:109715. doi: 10.1016/j.neuropharm.2023.109715
   PubMed Web of Science ®Google Scholar
• Salzman C, Kochansky GE, Van Der Kolk BA, et al. The effect of marijuana on small group process. Am J Drug Alcohol Abuse. 1977;4(2):251–255. doi: 10.3109/00952997709002763
   PubMed Web of Science ®Google Scholar
• Salzman CV, Shader RI. Marijuana and hostility in a small-group setting. Am J Psychiatry. 1976;133(9):1029–1033.
   PubMed Web of Science ®Google Scholar
• Kamal BS, Kamal F, Lantela DE. Cannabis and the anxiety of fragmentation-a systems approach for finding an anxiolytic cannabis chemotype. Front Neurosci. 2018;12:730. doi: 10.3389/fnins.2018.00730
   PubMed Web of Science ®Google Scholar
• Ferber SG, Namdar D, Hen-Shoval D, et al. The “entourage effect”: terpenes coupled with Cannabinoids for the treatment of mood disorders and anxiety disorders. Curr Neuropharmacol. 2020;18(2):87–96. doi: 10.2174/1570159X17666190903103923
   PubMed Web of Science ®Google Scholar
• Staben J, Koch M, Reid K, et al. Cannabidiol and cannabis-inspired terpene blends have acute prosocial effects in the BTBR mouse model of autism spectrum disorder. Front Neurosci. 2023;17:1185737. doi: 10.3389/fnins.2023.1185737
   PubMed Web of Science ®Google Scholar
• Savino R, Medoro A, Ali S, et al. The emerging role of flavonoids in autism spectrum disorder: a systematic review. J Clin Med. 2023 May 17;12(10):3520. doi: 10.3390/jcm12103520
   PubMed Web of Science ®Google Scholar
• Russo EB. The case for the entourage effect and conventional breeding of clinical cannabis: no “strain,” no gain. Front Plant Sci. 2018;9:1969. doi: 10.3389/fpls.2018.01969
   PubMed Web of Science ®Google Scholar
• Aran A, Harel M, Cassuto H, et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism. 2021 Feb 3;12(1):6. doi: 10.1186/s13229-021-00420-2
   PubMed Web of Science ®Google Scholar
• Silva EAD Jr, Medeiros WMB, Santos JPMD, et al. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind and controlled placebo clinical trial.Trends Psychiatry Psychother. 2022 May 26 ;44. Epub ahead of print. PMID: 35617670.
   Google Scholar
• Bearss K, Johnson C, Smith T, et al. Effect of parent training vs parent education on behavioral problems in children with autism spectrum disorder: a randomized clinical trial. JAMA. 2015 Apr 21;313(15):1524–33. doi: 10.1001/jama.2015.3150
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Hagerman R, Budimirovic D, et al. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). J Neurodev Disord. 2022 Nov 25;14(1):56. doi: 10.1186/s11689-022-09466-6
   PubMed Web of Science ®Google Scholar
• Pietropaolo S, Marsicano G. The role of the endocannabinoid system as a therapeutic target for autism spectrum disorder: Lessons from behavioral studies on mouse models. Neurosci Biobehav Rev. 2022 Jan;132: 664–678. doi: 10.1016/j.neubiorev.2021.11.031
   PubMed Web of Science ®Google Scholar
• Cheroni C, Caporale N, Testa G. Autism spectrum disorder at the crossroad between genes and environment: contributions, convergences, and interactions in ASD developmental pathophysiology. Mol Autism. 2020 Sep 10;11(1):69. doi: 10.1186/s13229-020-00370-1
   PubMed Web of Science ®Google Scholar
• Aran A, Harel M, Ovadia A, et al. Mediators of placebo response to cannabinoid treatment in children with autism spectrum disorder. J Clin Med. 2023 Apr 24;12(9):3098. doi: 10.3390/jcm12093098
   PubMed Web of Science ®Google Scholar